{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059656","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.655925+00:00","generated_at":"2026-06-02T03:23:54.789841+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CEO Joseph Ciaffoni steps down; Chairman Michael Heffernan named Interim CEO","bullets":["Joseph Ciaffoni to step down as President and CEO effective May 24, 2024.","Ciaffoni will not stand for re-election to the Board at May 16 Annual Meeting; Board reduced from nine to eight.","Michael Heffernan, current Chairman, appointed Interim President and CEO effective May 24, 2024.","Heffernan to receive base salary at $291,666 annual rate (one-third of Ciaffoni's salary).","Board has initiated a search for a permanent President and CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059656","json":"https://secwatch.observer/filing/0001104659-24-059656.json","markdown":"https://secwatch.observer/filing/0001104659-24-059656.md","text":"https://secwatch.observer/filing/0001104659-24-059656.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924059656/0001104659-24-059656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924059656/tm2414016d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:23:54.789841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"141515a7a8","claim":"Joseph Ciaffoni departed as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"announced that Joseph Ciaffoni will step down as the President and Chief Executive Officer of Collegium Pharmaceutical, Inc. (the “Company”) effective May 24, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924059656/0001104659-24-059656-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"5ff41eadeb","claim":"Michael Heffernan was appointed as Interim President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"the Board approved the appointment of Michael Heffernan, the Company’s Chairman of the Board, to Interim President and Chief Executive Officer, effective May 24, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924059656/0001104659-24-059656-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}